secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2023-12-26T23:59:59+00:00
Accession:  0001104659-23-129007
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome to acquire Atreca antibody assets for $5.5M upfront plus up to $7M milestones
--------------------------------------------------------------------------------

- Upfront cash payment of $5.5 million; additional $7.0 million in clinical development milestones.
- Assets include certain antibody-related assets and materials from Atreca, Inc.
- Transaction subject to customary conditions and Atreca stockholder approval.
- Immunome expects to expand its pipeline with the acquired assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923129007/0001104659-23-129007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923129007/tm2333682d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-129007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer